Guidelines for the diagnosis and treatment of COVID-19 in intensive care units
SOBRE ESTE GUIA
Este é um guia de referência rápida que resume as recomendações da Superintendência de Atenção Primária (S/SUBPAV/SAP) para o diagnóstico e o manejo na atenção primária da infecção pelo novo coronavírus. O documento representa o posicionamento da S/SUBPAV/SAP e tem a... função de orientar a assistência clínica nas unidades de atenção primária na cidade do Rio de Janeiro. Em caso de condutas divergentes do que estiver presente neste guia, recomenda-se o devido registro da justificativa em prontuário. Por
ser um campo em constante mudança, este guia será atualizado regularmente, e a versão mais recente estará disponível no site da SUBPAV (www.subpav.org) e no site www.coronavirus.rio, com uma lista das atualizações e suas respectivas datas.
more
ObjetivoEl objetivodel documento es servir de guía de actuación para el manejo casos de COVID-19 en atención primaria.3.Recomendaciones generalesSe recomienda la colocación de información visual (carteles, folletos, etc.) en lugares estratégicosde los centros de atenció...n primaria (de ahora en adelante CAP)para proporcionar a la poblaciónlas instrucciones sobre higiene de manosehigiene respiratoria.Se ofrecerá una mascarilla quirúrgica a aquellos pacientes que acudan al centro sanitario con síntomas de infección respiratoria aguda.Se debedisponer de dispensadores con solución hidroalcohólica al alcance de la poblacióny el personal. Se deberá disponer de contenedores de residuos, con tapa de apertura con pedal, para la eliminación de los residuos generados.
more
To provide quality maternal and newborn health services at health facilities in India.
This guideline is for:
• health and care practitioners
• health and care staff involved in planning and delivering services
• commissioners.
The recommendations bring together:
• existing national and international guidance and policies
• advice from specialists working in the NHS fr...om across the UK. These include people with
expertise and experience of treating patients for the specific health conditions covered by the
guidance during the current COVID-19 pandemic.
more
WHO recently conducted a survey to assess the availability and cost of a national tracer list of essential medicines in the outpatient sector in Ukraine using a new collection tool – the WHO Essential Medicines and Health Products Price and Availability Monitoring Mobile Application. This tool fac...ilitates rapid and inexpensive data collection at the facility level.
more
This manual was developed based on the recommendations of a global technical consultation on child health in humanitarian emergencies co-organized by WHO and UNICEF at the end of 2003. WHO in collaboration with the Centre for Refugee and Disaster Response, Bloomberg School of Public Health, Johns Ho...pkins University undertook a systematic review in 2004. It demonstrated that existing guidelines, including The Integrated Management of Childhood Illness (IMCI), do not cover all priority conditions in emergencies. The objective of this manual is to provide comprehensive guidance on child care in emergencies.
more
DESIGN OF THIS CASE REPORT FORM (CRF)This CRF has 3 modules:Module 1to be completed on the first day of admission to the health centre.Module 2 to be completed daily during hospital stay for as many days as resources allow. Continue to follow-up patients who transfer between wards. Module 3 to be co...mpleted at discharge or death
more
Guia rápido para profissionais de saúde
Q&A on COVID-19, HIV and antiretrovirals - Hỏi Đáp về COVID-19, HIV và thuốc antiretrovirals (ARVs)
A practical tool to help health workers in the clinical and operational management of multidrug-resistant tuberculosis with special focus on the introduction, implementation and management of the nine-month treatment regimen.
Los datos preliminares de eficacia se infirieron mediante un enfoque de “inmunogenicidad puente”, en el que los títulos neutralizantes obtenidos después de la vacuna en niños y niñas de 5 a 11 años se compararon con los títulos obtenidos en adolescentes de 16 a 25 años (en quienes se hab...a evaluado la eficacia).Entre los participantes sin evidencia de infección previa por SARS-CoV-2, hubo 3 casos de COVID-19 entre los 1.305 receptores de vacuna a partir de los 7 días de la segunda dosis y 16 entre los 663 receptores de placebo.
more
A review of prospects for existing antibiotics ad new therapeutics
La dosis de refuerzo está indicada una vez transcurridos los 4 meses (120 días) de la última dosis del esquema inicial y será con vacuna de plataforma ARNm: Pfizer-BioNTech pediátrica a partir de los 5 años o Moderna para uso pediátrico a partir de los 6 años.
The report discusses the epidemiological and social aspects of ageing, health and functional changes experienced with ageing, the impact of physical activity, assessment of the nutritional status of older persons, and nutritional guidelines for healthy ageing.